Balancing intellectual monopoly privileges and the need for essential medicines

This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS agreement and the recent policy debate regarding the protection of public health interest, particularly as they pertain to the Doha Declaration. In this editorial, we consider the debate, the conclusion...

Descripción completa

Detalles Bibliográficos
Autores principales: Martin, Greg, Sorenson, Corinna, Faunce, Thomas
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904211/
https://www.ncbi.nlm.nih.gov/pubmed/17565684
http://dx.doi.org/10.1186/1744-8603-3-4
_version_ 1782133971533955072
author Martin, Greg
Sorenson, Corinna
Faunce, Thomas
author_facet Martin, Greg
Sorenson, Corinna
Faunce, Thomas
author_sort Martin, Greg
collection PubMed
description This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS agreement and the recent policy debate regarding the protection of public health interest, particularly as they pertain to the Doha Declaration. In this editorial, we consider the debate, the conclusions thereof, and identify five questions that should be considered by key stakeholders in ongoing discussions.
format Text
id pubmed-1904211
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-19042112007-06-29 Balancing intellectual monopoly privileges and the need for essential medicines Martin, Greg Sorenson, Corinna Faunce, Thomas Global Health Editorial This issue of Globalization and Health presents a paper by Kerry and Lee that considers the TRIPS agreement and the recent policy debate regarding the protection of public health interest, particularly as they pertain to the Doha Declaration. In this editorial, we consider the debate, the conclusions thereof, and identify five questions that should be considered by key stakeholders in ongoing discussions. BioMed Central 2007-06-12 /pmc/articles/PMC1904211/ /pubmed/17565684 http://dx.doi.org/10.1186/1744-8603-3-4 Text en Copyright © 2007 Martin et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Editorial
Martin, Greg
Sorenson, Corinna
Faunce, Thomas
Balancing intellectual monopoly privileges and the need for essential medicines
title Balancing intellectual monopoly privileges and the need for essential medicines
title_full Balancing intellectual monopoly privileges and the need for essential medicines
title_fullStr Balancing intellectual monopoly privileges and the need for essential medicines
title_full_unstemmed Balancing intellectual monopoly privileges and the need for essential medicines
title_short Balancing intellectual monopoly privileges and the need for essential medicines
title_sort balancing intellectual monopoly privileges and the need for essential medicines
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1904211/
https://www.ncbi.nlm.nih.gov/pubmed/17565684
http://dx.doi.org/10.1186/1744-8603-3-4
work_keys_str_mv AT martingreg balancingintellectualmonopolyprivilegesandtheneedforessentialmedicines
AT sorensoncorinna balancingintellectualmonopolyprivilegesandtheneedforessentialmedicines
AT fauncethomas balancingintellectualmonopolyprivilegesandtheneedforessentialmedicines

Ejemplares similares